 Epigenetics is the study of changes in gene expression that do not involve alterations to the underlying DNA sequence. These changes can occur through mechanisms such as DNA methylation, histone modifications, and non-coding RNA production. Epigenetic changes have been observed in many types of cancer, and they can lead to abnormal cell growth and proliferation, as well as increased resistance to chemotherapeutic drugs. In recent years, researchers have begun to explore the potential of epigenetic therapies for treating cancer. This includes targeted treatments that aim to restore normal epigenetic patterns in cancerous cells, as well as broader approaches that seek to manipulate the tumor microenvironment to promote anti-tumor immunity. Despite some successes, these approaches have yet to produce significant improvements in patient outcomes. One possible explanation for this is that current epigenetic therapies lack the ability to target specific components of the tumor microenvironment, leading to unintended side effects and poor efficacy. To address this issue, researchers have developed novel epigenetic-based drug delivery systems that can selectively target and deliver therapeutic agents to the tongue. This article was authored by Jiusin Zhang, Li Huang, Guangbo Gu, and others.